Application of CDK12 protein and its encoding gene in the preparation of antiviral drugs

Through the interaction between CDK12 protein and FHV virulence factor B2, RNA interference signaling pathways are activated and FHV virus replication is inhibited, and the problem of unclear function of CDK12 in antiviral immunity is solved, and effective inhibition of envelopeless viruses is achieved. New antiviral treatment options were made.

CN117899202BActive Publication Date: 2024-11-26HANGZHOU NORMAL UNIVERSITY
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410083959.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-19
Publication Date
2024-11-26
Estimated Expiration
2044-01-19

AI Technical Summary

Technical Problem

The function and mechanism of CDK12 in antiviral immunity are unclear, and the prior art is difficult to effectively inhibit the replication of unencapsulated viruses such as Frankhouse virus in host cells.

Method used

Using CDK12 protein to interact with FHV virulence key protein B2, activate RNA interference with antiviral signaling pathways, thereby inhibiting the replication of FHV virus in the host, providing CDK12 protein and its encoding genes as antiviral drugs, including pharmaceutically acceptable vectors and excipients, used to prepare antiviral drugs, RNA interference immune enhancers and B2 protein inhibitors.

Benefits of technology

By targeting FHV's key virulence factor B2, it weakens its inhibitory effect on the RNA interference pathway, enhances RNA interference antiviral immunity, and thus inhibits the replication of FHV in host cells, providing new antiviral drug development targets and treatment plans. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117899202B_ABST
    Figure CN117899202B_ABST
Patent Text Reader

Abstract

The present invention discloses the use of CDK12 protein and its encoding gene in the preparation of antiviral drugs. The present invention provides the role and mechanism of CDK12 protein with amino acid sequence as shown in SEQ ID NO.2 and CDK12 protein encoding gene with nucleic acid sequence as shown in SEQ ID NO.1 in antiviral immunity. Specifically, CDK12 protein interacts with B2 protein, a key protein of FHV virulence, and activates RNA interference antiviral signaling pathway, thereby inhibiting the replication of FHV virus in the host. The present invention provides a new target for the development of antiviral drugs and provides a scientific basis for the proposal of new antiviral treatment schemes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of bioengineering and relates to the application of a CDK12 protein and a coding gene thereof in the preparation of antiviral drugs. Background Art

[0002] Viral infection is one of the major risk factors threatening human health and socioeconomic development. Innate immunity is the body's first line of defense against viral invasion and plays a critical role in the body's immune response to clear viruses. Because fruit flies lack adaptive immune responses and their innate immunity is highly conserved with that of mammals such as humans during evolution, fruit flies have always been a powerful model for studying antiviral innate immunity.

[0003] RNAi is a cellular mechanism that regulates gene expression at the post-transcriptional level in eukaryotes and is considered to be a natural antiviral immune defense mechanism in fungi, plants, invertebrates, and mammals. RNA interference is the main antiviral immunity of Drosophila. In order to counter the host's RNA interference antiviral pathway, many viruses have evolved RNA interference suppressors, called VSRs (viral suppressors of RNAi), such as the 3A protein encoded by human enterovirus and the NS1 protein encoded by influenza virus in mammalian viruses; the 1A protein encoded by Drosophila C virus that infects Drosophila and the VP3 protein encoded by Drosophila X virus. VSRs are important virulence factors of viruses and are the guarantee for the efficient replication of viruses in the host. Flock House Virus (FHV) belongs to the family of Tanomuraviridae and is a non-enveloped virus with a very wide host range. It can replicate and reproduce in mammalian cells, insects, plants, and nematodes, and is widely used in the study of the interaction mechanism between viruses and host RNA interference pathways. B2 is a VSR encoded by FHV and is an important protein for the proliferation of FHV in Drosophila. It inhibits the RNA interference pathway through multiple mechanisms, including: (1) binding to double-stranded RNA produced by the virus, inhibiting the recognition of these viral double-stranded RNAs by the RNA interference pathway; (2) directly binding to the key protein DCR-2 in the RNA interference pathway, inhibiting the activity of this protein.

[0004] Cyclin-dependent kinase 12 (CDK12) is a serine / threonine protein kinase that is highly conserved in evolution. Drosophila CDK12 is homologous to a pair of human isozymes CDK12 / CDK13, especially the sequence of the catalytic kinase domain is highly conserved. The most typical role of CDK12 is to phosphorylate threonine residues of RNA polymerase II, and this modification regulates the initiation, elongation, splicing and polyadenylation of mRNA transcription. Studies have shown that CDK12 does not regulate global gene expression, but is genetically selective for genes involved in cell stress, heat shock, DNA damage response and learning. In addition, new research reports indicate that CDK12 can regulate cell signaling pathways and immune pathways related to tumor occurrence and development, including c-MYC / β-catenin, ErbB–PI3K–AKT, WNT, MAPK, non-classical NF-κB and DNA damage response signal transduction.

[0005] However, the function and mechanism of CDK12 in antiviral immunity remain unclear and require further study. Summary of the invention

[0006] The first objective of the present invention is to provide an application of CDK12 protein in the preparation of antiviral drugs in view of the deficiencies in the prior art.

[0007] In order to achieve the above-mentioned object of the invention, the present invention is implemented by the following technical solutions:

[0008] The use of CDK12 protein in the preparation of antiviral drugs, wherein the virus is a non-enveloped virus; the amino acid sequence of the CDK12 protein is shown in SEQ ID NO.2.

[0009] Preferably, the non-enveloped virus is Frankhausen virus (FHV).

[0010] Preferably, the CDK12 protein interacts with the FHV virulence key protein B2 protein, activating the RNA interference antiviral signaling pathway, thereby inhibiting the replication of the FHV virus in the host.

[0011] The second object of the present invention is to provide an application of a gene encoding a CDK12 protein in the preparation of an antiviral drug, wherein the virus is a non-enveloped virus; the nucleic acid sequence of the gene encoding the CDK12 protein is shown in SEQ ID NO.1.

[0012] Preferably, the non-enveloped virus is Frankhausen virus (FHV).

[0013] In the present invention, the CDK12 protein and its encoding gene are from Drosophila melanogaster.

[0014] The third object of the present invention is to provide an antiviral drug comprising CDK12 protein and / or its encoding gene, wherein the virus is a non-enveloped virus.

[0015] Preferably, the drug further comprises a pharmaceutically acceptable carrier and / or excipient.

[0016] The fourth object of the present invention is to provide the use of CDK12 protein in the preparation of viral replication inhibitors.

[0017] The fifth object of the present invention is to provide the use of CDK12 protein in the preparation of RNA interference immune enhancer.

[0018] The sixth objective of the present invention is to provide an application of CDK12 protein in the preparation of a B2 protein inhibitor, where overexpression of CDK12 inhibits the protective function of B2 protein against viruses.

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] The present invention provides an application of CDK12 protein in the preparation of antiviral drugs. The antiviral protein CDK12 targets the key virulence factor B2 of FHV, weakens the inhibitory effect of B2 on the RNA interference pathway, enhances RNA interference antiviral immunity, and thus inhibits the replication of FHV in host cells. The present invention provides a new target for the development of antiviral drugs and provides a scientific basis for the proposal of new antiviral treatment schemes. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 This is a diagram showing the results of using co-immunoprecipitation experiments to confirm the interaction between CDK12 and FHV key virulence factor B2.

[0022] Figure 2 This is a diagram showing the results of using the dual luciferase system to prove that CDK12 weakens the inhibitory function of B2 on the RNA interference pathway.

[0023] Figure 3 This figure shows the results of real-time fluorescence quantitative PCR detection of intracellular viral RNA in Drosophila S2 cells with silenced CDK12 after FHV infection.

[0024] Figure 4 This is the result of real-time fluorescence quantitative PCR detection of intracellular viral RNA after FHV infected Drosophila S2 cells overexpressing CDK12.

[0025] Figure 5 This is the result of real-time fluorescence quantitative PCR detection of intracellular viral RNA of B2 mutant FHV in CDK12 silenced cells in the presence or absence of B2 protein.

[0026] Figure 6 This is the result of real-time fluorescence quantitative PCR detection of intracellular viral RNA of B2 mutant FHV in CDK12 overexpressing cells in the presence or absence of B2 protein. DETAILED DESCRIPTION

[0027] The present invention is further described in detail below in conjunction with the accompanying drawings and specific examples of the specification. The examples are only used to explain the present invention and are not used to limit the present invention. The test methods used in the following examples are conventional methods unless otherwise specified; the materials and reagents used are all commercially available materials and reagents unless otherwise specified.

[0028] Materials, reagents, and instruments

[0029] Cell culture medium: Drosophila culture medium was purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd., fetal bovine serum was purchased from LONSERA, and 100U / ml penicillin-streptomycin was purchased from GIBCO. Complete Drosophila culture medium (10% fetal bovine serum and 1% penicillin-streptomycin)

[0030] Cells: Drosophila S2 cells (preserved in the inventor's laboratory)

[0031] Plasmids: Psi-CHECK2, pMT-V5 / HisA, and pMT-GFP (preserved by the inventors);

[0032] pMT-V5-CDK12 and pMT-B2-GFP were constructed by the inventors.

[0033] Reagents: Trizol RNA extraction reagent was purchased from Tiangen Company, and reverse transcription kit was purchased from Fermentas Company in the United States; cloning kit, T7 in vitro transcription kit and quantitative PCR reagent were purchased from Novartis Company; BeoECL plus chemiluminescent substrate was purchased from Beyotime Company; ProteinAagarose and GFP antibody were purchased from Santa Cruz Company; transfection reagent lipo3000 and V5 antibody were purchased from Invitrogen Company; dual luciferase detection kit was purchased from Promega Company.

[0034] Consumables: 12-well cell culture plates and T25 cell culture flasks were purchased from NEST; cell culture medium filters were purchased from Corning.

[0035] Instruments: Chemiluminescence developer: Fluorescence quantitative PCR instrument: QuantStudio 7Flex system, Life Technologies; Fusion FX SPECTRA, VILBER; Multifunctional microplate reader: Varioskan Flash, Thermo; Low-temperature centrifuge: 5425R, Eppendorf.

[0036] The nucleic acid sequence of the gene encoding the CDK12 protein of the present invention (SEQ ID NO.1):

[0037]

[0038] The amino acid sequence of the CDK12 protein of the present invention (SEQ ID NO.2):

[0039]

[0040] 1. Experimental Methods

[0041] 1. Construction of recombinant plasmids pMT-V5-CDK12 and pMT-B2-GFP.

[0042] (1) Total RNA from Langhausen virus-infected Drosophila cells was extracted by Trizol method and reverse transcribed to obtain cDNA.

[0043] (2) Using the cDNA obtained in step (1) as a template, PCR amplification was performed using V5-CDK12-F and pMT-CDK12-R to obtain a CDK12 fragment with a partial V5 tag sequence, and then the fragment was used as a template to perform PCR amplification using pMT-V5-F and CDK12-R to obtain a V5-CDK12 fragment with pMT homology arms at both ends. Using the cDNA obtained in step 1 as a template, PCR amplification was performed using pPMT-B2-F and GFP-B2-R to obtain a B2 fragment with a pMT homology arm at the 5' end and a GFP homology arm at the 3' end. The primer sequences are as follows (the underlined sequence represents the homology arm portion):

[0044] V5-CDK12-F (SEQ ID NO. 3)

[0045] TATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCATGCATCCTCCGCG GCGGC

[0046] pMT-CDK12-R (SEQ ID NO.4)

[0047] GAAGGGCCCTCTAGACTCGAG CTAAGCATCCCCCACCATGG

[0048] V5-F (SEQ ID NO.5)

[0049] GGGATCTAGATCGGGGTACC GCCACCATGGGTAAGCCTATCCCTAACC CTCTCCTCG

[0050] pMT-B2-F (SEQ ID NO.6)

[0051] GGGATCTAGATCGGGGTACC GCCACCATGCCAAGCAAACTCGCGCTAAGFP-B2-R(SEQ ID NO.7)

[0052] TCCTCGCCCTTGCTCACCAT CAGTTTTGCGGGTGG

[0053] (3) The pMT-V5 / HisA and pMT-GFP plasmids were double-digested with restriction endonucleases KpnI and XbaI to recover the backbone vector fragment.

[0054] (4) The PCR product obtained in step (2) and the vector obtained in step (3) were subjected to a recombination reaction, and the recombination reaction product was transformed into competent cells DH5α. Colony PCR was performed on the recombinant plasmid to obtain colonies positive for the recombinant plasmid, and then the recombinant plasmid was sequenced for verification. The sequencing results showed that the CDK12 gene sequence shown in SEQ ID NO.2 was inserted into the plasmid pMT-V5 / HisA. The B2 gene sequence shown in SEQ ID NO.8 was inserted into the plasmid pMT-GFP.

[0055] B2 gene sequence (SEQ ID NO.8)

[0056] ATGCCAAGCAAACTCGCGCTAATCCAGGAACTTCCCGACCGCATTCAAACGGCGGTGGAAGCAGCCATGGGAATGAGCTACCAAGACGCACCGAACAACGTGCGCAGGGACCTCGACAACCTGCACGCTTGCCTAAACAAGGCAAAACTAACGGTAAGTCGGATGGTAACATCACTGCTGGAGAAACCCAGCGTGGT GGCATACCTAGAGGGAAAGGCCCCCGAGGAGGCAAAACCAACACTCGAAGAACGCCTCCGAAAGCTGGAGCTCAGCCACAGCCTTCCAACAACCGGAAGTGACCCCCCACCCGCAAAACTG

[0057] 2. Plate an appropriate amount of cells into a T25 cell culture flask, and use the transfection reagent lipo3000 to transfer the recombinant plasmid pMT-V5-CDK12 and pMT-B2-GFP or pMT-GFP into S2 cells. 24 hours after transfection, add CuSO4 with a final concentration of 0.5mM to induce for 24 hours.

[0058] 3. Co-immunoprecipitation experiment.

[0059] (1) Collect the transfected cells, centrifuge at 200×g for 5 min, discard the original culture medium, and wash the cells with pre-cooled 1× PBS.

[0060] (2) Add 1 ml of RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 10% Glycerol, 1% Nonidet P-40 and 1 mM PMSF) to the cell pellet and place on ice for 30 min, mixing by shaking every 10 min.

[0061] (3) After centrifugation at 13,000 rpm and 4°C for 10 min, the supernatant was collected and 50 μl of protein Aagarose was added and incubated at room temperature for 1 h to remove non-specific binding.

[0062] (4) Incubate V5 antibody, GFP antibody and IgG antibody with proteinAagarose at room temperature for 1 hour to pre-crosslink the antibodies to proteinAagarose.

[0063] (5) Take 30 μl of lysate as input. Add protein A agarose pre-crosslinked with V5 antibody and IgG antibody to 500 μl of cell lysate co-transfected with pMT-V5-CDK12 and pMT-B2-GFP, and add protein A agarose pre-crosslinked with GFP antibody and IgG antibody to 500 μl of cell lysate co-transfected with pMT-V5-CDK12 and pMT-GFP. Add protein A agarose pre-crosslinked with GFP antibody and IgG antibody to 500 μl of cell lysate co-transfected with pMT-V5-CDK12 and pMT-GFP, and incubate at 4°C with slow shaking overnight.

[0064] (6) The overnight reaction was centrifuged at 200 × g at 4°C for 5 min, and the beads were then washed five times with RIPA lysis buffer.

[0065] 4. Immunoblotting experiment.

[0066] (1) The obtained protein sample was added with 1× SDS loading buffer and boiled for 5 min to elute the protein on the beads.

[0067] (2) Subject the protein sample to reducing SDS-PAGE and stop electrophoresis after bromophenol blue is ejected from the gel.

[0068] (3) The PVDF membrane was activated with methanol for 5 min. Then, the membrane was transferred at 200 mM in an ice-water bath for 90-120 min using the sandwich method.

[0069] (4) Remove the PVDF membrane and block it with a blocking solution containing 5% skim milk powder for 1 hour. Incubate with primary antibodies against V5, GFP, and β-tubulin at 4°C overnight.

[0070] (5) Wash the membrane with TBST for 5 min each time, repeat 5 times. Incubate with secondary antibody at room temperature for 1 h, then wash the membrane with TBST for 5 min each time, repeat 5 times.

[0071] (6) Detection is performed using a chemiluminescent substrate and development analysis is performed using a chemiluminescent developer.

[0072] 2. Experimental Results

[0073] Results Figure 1 As shown, co-immunoprecipitation experiments demonstrated that CDK12 and FHV key virulence factor B2 formed a complex, while CDK12 and non-specific protein GFP did not bind to each other, demonstrating the specific binding of CDK12 and B2.

[0074] Example 2: Detecting the effect of CDK12 on the host RNA interference pathway

[0075] 1. Experimental Methods

[0076] 1. Preparation of dsRNA.

[0077] (1) The primers designed for preparing dsRNA encoding DNA targeting three different regions of the CDK12 gene are as follows (the underlined region is the T7 promoter sequence):

[0078] CDK12-T7-F1 (SEQ ID NO.9)

[0079] TAATACGACTCACTATAGGG CATGGATCACGACTTGATGG

[0080] CDK12-T7-R1 (SEQ ID NO. 10)

[0081] TAATACGACTCACTATAGGG CAAGCATTTTTGTCCAGCAGA

[0082] CDK12-T7-F2 (SEQ ID NO.11)

[0083] TAATACGACTCACTATAGGG TCGAGCAGTCACGATACCAG

[0084] CDK12-T7-R2 (SEQ ID NO. 12)

[0085] TAATACGACTCACTATAGGG AGTAGCGATCGCCAGAGGTA

[0086] CDK12-T7-F3 (SEQ ID NO. 13)

[0087] TAATACGACTCACTATAGGG ATCAATGCCTTACTGGACCG

[0088] CDK12-T7-R3 (SEQ ID NO. 14)

[0089] TAATACGACTCACTATAGGG TGATGCGCACTTACATCCTC

[0090] (2) Total RNA was extracted from Drosophila S2 cells and reverse transcribed into cDNA. The cDNA was used as a template and PCR amplification was performed using the three pairs of primers of the CDK12 gene mentioned above, and the PCR amplification products were recovered.

[0091] (3) Take the PCR product obtained in step (2), and perform in vitro transcription using a T7 in vitro transcription kit to obtain a double-stranded RNA molecule (i.e., dsRNA targeting the CDK12 gene) after the reaction. Purify the dsRNA using the Trizol method.

[0092] (4) The primers designed for preparing the coding DNA for dsRNA targeting the β-gal gene are as follows (the underlined region is the T7 promoter sequence):

[0093] β-gal-T7-F (SEQ ID NO.15)

[0094] TAATACGACTCACTATAGGG CGTTTTTCCATAGGCTCC

[0095] β-gal-T7-R (SEQ ID NO.16)

[0096] TAATACGACTCACTATAGGG CTTCAAGAACTCTGTAGCAC

[0097] (5) Using the DH5α strain as a template and the above-mentioned β-gal gene primer pair, PCR amplification was performed and the PCR amplification product was recovered.

[0098] (6) Take the PCR product obtained in step (5), and use a T7 in vitro transcription kit to perform in vitro transcription to obtain a double-stranded RNA molecule (i.e., dsRNA targeting the β-gal gene) after the reaction. Use the Trizol method to purify the dsRNA.

[0099] (7) The primers designed for preparing the coding DNA of dsRNA targeting the firefly luciferase gene are as follows (the underlined region is the T7 promoter sequence):

[0100] Firefly-T7-F (SEQ ID NO.17)

[0101] TAATACGACTCACTATAGGG GGACATCACCTATGCCGAGT

[0102] Firefly-T7-R (SEQ ID NO.18)

[0103] TAATACGACTCACTATAGGG CGGTAGACCCAGAGCTGTTC

[0104] (8) Using the psi-CHECK2 plasmid as a template, the above-mentioned firefly luciferase gene primer pair was used for PCR amplification, and the PCR amplification product was recovered.

[0105] (9) Take the PCR product obtained in step (8), and perform in vitro transcription using a T7 in vitro transcription kit to obtain a double-stranded RNA molecule (i.e., dsRNA targeting the firefly luciferase gene) after the reaction. Purify the dsRNA using the Trizol method.

[0106] 2. In a 12-well cell culture plate, add 400 μl of serum-free medium cell suspension (4×10 6 The cells were incubated with 7 μg of dsRNA (experimental group: three CDK12 dsRNAs, control group: β-gal dsRNA) at 25°C for 30 min, and then a complete medium containing 20% ​​serum was added to make the final concentration of serum reach 10%. The cells were cultured at 25°C for 2 days to obtain cells with silenced CDK12 gene expression.

[0107] 3. Re-plated the cells in step 2 into a new 12-well plate, and co-transfected psi-CHECK2 and pMT-B2-GFP plasmids or psi-CHECK2 and pMT-GFP plasmids into S2 cells using the transfection reagent lipo3000. After transfection for 24 hours, add CuSO4 with a final concentration of 0.5 mM to induce for 24 hours.

[0108] 4. Use dsRNA targeting the firefly luciferase gene expressed by the psi-CHECK plasmid to mediate RNA interference pathway to silence the expression of the firefly luciferase gene, and use the firefly luciferase gene expression level to evaluate the efficiency of the RNA interference pathway in each cell. The specific steps are as follows:

[0109] (1) In a 12-well cell culture plate, add 400 μl of serum-free medium containing the cell suspension (4 × 10 6 Cells were incubated with 7 μg of luciferase gene dsRNA at 25°C for 30 min, and then complete medium containing 20% ​​serum was added to make the final concentration of serum reach 10%. The cells were cultured at 25°C for 2 days.

[0110] (2) Collect the cells from step 4, centrifuge at 200×g for 5 min, discard the original culture medium, and wash the cells with pre-cooled 1×PBS. Use a dual luciferase detection kit and a multi-function microplate reader to detect the activities of firefly luciferase and Renilla luciferase (as a transfection control), and calculate the activity ratio of firefly luciferase to Renilla luciferase.

[0111] 2. Experimental Results

[0112] Results Figure 2 As shown, the dual luciferase reporter system experiment proved that B2 protein inhibited the RNA interference pathway, and CDK12 weakened the inhibitory effect of B2 on the RNA interference pathway.

[0113] Example 3: Detection of the effect of intracellular CDK12 on FHV replication

[0114] 1. Experimental Methods

[0115] 1. Effect of intracellular silencing of CDK12 expression on FHV replication

[0116] (1) According to the method in Example 2, cells with silenced CDK12 gene expression and control cells were obtained.

[0117] (2) Infected with FHV, MOI = 1, and cells were collected after 24 hours.

[0118] (3) Total RNA from virus-infected cells was extracted by Trizol method, reverse transcribed into cDNA, and then the viral RNA level was detected by quantitative PCR. The primers used were as follows:

[0119] FHV-qPCR-F (SEQ ID NO.19)

[0120] TGACCGACAAGAATGAACT

[0121] FHV-qPCR-R (SEQ ID NO.20)

[0122] TGTCCCATACCGATAAGC

[0123] RP49-qPCR-F (SEQ ID NO.21)

[0124] AGCATACAGGCCCAAGATCG

[0125] RP49-qPCR-R (SEQ ID NO. 22)

[0126] TGTTGTCGATACCCTTGGGC

[0127] The results are shown in Figure 3As shown, silencing CDK12 expression in cells can enhance the replication of FHV.

[0128] 2. Effect of intracellular overexpression of CDK12 on FHV replication

[0129] (1) An appropriate amount of cells were plated into a 12-well plate, and the recombinant plasmid pMT-V5-CDK12 or pMT-GFP was transferred into S2 cells using the transfection reagent lipo3000. 24 hours after transfection, CuSO4 with a final concentration of 0.5 mM was added for induction for 24 hours.

[0130] (2) FHV, MOI=1, cells were collected after 24 hours.

[0131] (3) The total RNA of virus-infected cells was extracted by Trizol method, reverse transcribed into cDNA, and then the viral RNA level was detected by quantitative PCR.

[0132] Results Figure 4 As shown, intracellular overexpression of CDK12 can inhibit the replication of FHV.

[0133] 2. Experimental Results

[0134] In summary, Example 3 illustrates that silencing CDK12 expression in cells can enhance the replication of FHV, while overexpressing CDK12 can inhibit the replication of FHV.

[0135] Example 4: Detection of the effect of CDK12 on the function of B2 protein in protecting viral replication

[0136] 1. Experimental Methods

[0137] 1. The effect of intracellular silencing of CDK12 expression on the function of B2 protein in protecting viral replication.

[0138] (1) According to the method in Example 2, cells with silenced CDK12 gene expression and control cells were obtained.

[0139] (2) The cells were re-plated into a new 12-well plate, and the pMT-B2-GFP plasmid or pMT-GFP plasmid was transferred into S2 cells using the transfection reagent lipo3000. CuSO4 with a final concentration of 0.5 mM was added 24 hours after transfection to induce for 24 hours.

[0140] (3) Infected with B2 mutant FHV, and the cells were collected after 24 h.

[0141] (4) The total RNA of virus-infected cells was extracted by Trizol method, reverse transcribed into cDNA, and then the viral RNA level was detected by quantitative PCR.

[0142] The results are shown in Figure 5As shown, silencing CDK12 did not affect the replication of B2 mutant FHV, but significantly increased the replication of B2 mutant FHV in B2-expressing cells.

[0143] 2. The effect of intracellular overexpression of CDK12 on the function of B2 protein in protecting viral replication.

[0144] (1) An appropriate amount of cells were plated into a 12-well plate, and the recombinant plasmids pMT-V5-CDK12 and pMT-B2-GFP or pMT-V5-CDK12 and pMT-GFP were co-transfected into S2 cells using the transfection reagent lipo3000. 24 hours after transfection, CuSO4 with a final concentration of 0.5 mM was added for induction for 24 hours.

[0145] (2) Infected with B2 mutant FHV, and the cells were collected after 24 h.

[0146] (3) The total RNA of virus-infected cells was extracted by Trizol method, reverse transcribed into cDNA, and then the viral RNA level was detected by quantitative PCR.

[0147] Results Figure 6 As shown, overexpression of CDK12 did not affect the replication of B2 mutant FHV, but significantly reduced the replication of B2 mutant FHV in B2-expressing cells.

[0148] 2. Experimental Results

[0149] In summary, Example 4 illustrates that silencing CDK12 expression in cells can promote the protective function of B2 against viruses, while overexpressing CDK12 can inhibit the protective function of B2 against viruses.

[0150] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. Application of CDK12 protein in the preparation of antiviral drugs, It is characterized in that The virus is Frankhausen virus FHV; the amino acid sequence of the CDK12 protein is shown in SEQ ID NO.

2.

2. The use according to claim 1, It is characterized in that CDK12 protein interacts with FHV virulence key protein B2 protein, activates RNA interference antiviral signaling pathway, and thus inhibits the replication of FHV virus in the host.

3. Application of the gene encoding CDK12 protein in the preparation of antiviral drugs, It is characterized in that The virus is Frankhausen virus FHV; the nucleic acid sequence of the encoding gene is shown in SEQ ID NO.

1.

4. Application of CDK12 protein in the preparation of viral replication inhibitors, It is characterized in that The virus is Frankhausen virus FHV, and the amino acid sequence of the CDK12 protein is shown in SEQ ID NO.2.

Citation Information

Patent Citations

  • 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors

    US20200345736A1